Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Delanzo DR vs Dexilant in Healthy Pakistani Subjects
NCT04877834Phase 1Completed
- Sponsor
- University of Karachi
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by University of Karachi. Primary endpoints: Maximum Plasma Concentration at 24 hours, Time to Maximum Plasma Concentration at 24 hours and 1 more. Started Sep 2021; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04877834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877834.